Drug Search Results
More Filters [+]

AZD1236

Alternative Names: azd1236
Latest Update: 2022-05-20
Latest Update Note: News Article

Product Description

AZD1236 is a potent and reversible inhibitor of human MMP-9 and MMP-12 (IC50 = 4.5 and 6.1nM, respectively), with >10-fold selectivity to MMP-2 and MMP-13 and >350-fold selectivity to other members of the enzyme family. AZD1236 activity is approximately 20 to 50-fold lower at the rat, mouse, and guinea pig orthologues. In acute models of lung injury, AZD1236 inhibited the haemorrhage and inflammation induced by instillation of human MMP-12 into rat lungs by ~80% at 0.81mg/kg, and also abolished macrophage infiltration into BAL fluid induced by tobacco smoke inhalation in the mouse. (Sourced from: https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd1236.html)

Mechanisms of Action: MMP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD1236

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Chronic Obstructive Pulmonary Disease|Cystic Fibrosis

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CYBER

P2

Terminated

Cystic Fibrosis

2009-08-28

BICO

P2

Completed

Chronic Obstructive Pulmonary Disease

2009-08-20

2008-002230-30

P2

Completed

Chronic Obstructive Pulmonary Disease

2009-07-21

BICO

P2

Completed

Chronic Obstructive Pulmonary Disease

2009-05-01

Recent News Events